Search

Your search keyword '"Verri, Carla"' showing total 22 results
Start Over Author "Verri, Carla" Search Limiters Full Text
22 results on '"Verri, Carla"'

5. Correction: Circulating microRNA signature as liquid-biopsy to monitor lung cancer in low-dose computed tomography screening

Author

Sestini, Stefano, primary, Boeri, Mattia, additional, Marchiano, Alfonso, additional, Pelosi, Giuseppe, additional, Galeone, Carlotta, additional, Verri, Carla, additional, Suatoni, Paola, additional, Sverzellati, Nicola, additional, Vecchia, Carlo La, additional, Sozzi, Gabriella, additional, and Pastorino, Ugo, additional

Published
2019
Full Text
View/download PDF

6. Circulating miRNAs and PD-L1 Tumor Expression Are Associated with Survival in Advanced NSCLC Patients Treated with Immunotherapy: a Prospective Study

Author

Boeri, Mattia, primary, Milione, Massimo, additional, Proto, Claudia, additional, Signorelli, Diego, additional, Lo Russo, Giuseppe, additional, Galeone, Carlotta, additional, Verri, Carla, additional, Mensah, Mavis, additional, Centonze, Giovanni, additional, Martinetti, Antonia, additional, Sottotetti, Elisa, additional, Pastorino, Ugo, additional, Garassino, Marina Chiara, additional, and Sozzi, Gabriella, additional

Published
2019
Full Text
View/download PDF

7. Complement C4d-specific antibodies for the diagnosis of lung cancer

Author

Ajona, Daniel, primary, Okrój, Marcin, additional, Pajares, María J., additional, Agorreta, Jackeline, additional, Lozano, María D., additional, Zulueta, Javier J., additional, Verri, Carla, additional, Roz, Luca, additional, Sozzi, Gabriella, additional, Pastorino, Ugo, additional, Massion, Pierre P., additional, Montuenga, Luis M., additional, Blom, Anna M., additional, and Pio, Ruben, additional

Published
2017
Full Text
View/download PDF

8. Abstract 2753: Mutational profiles from targeted NGS combine with miRNA-based liquid biopsy to predict survival in LDCT screening-detected lung cancers

Author

Boeri, Mattia, primary, Verri, Carla, additional, Borzi, Cristina, additional, Holscher, Todd, additional, Dugo, Matteo, additional, Devecchi, Andrea, additional, Romeo, Elisa, additional, Sestini, Stefano, additional, Suatoni, Paola, additional, Pastorino, Ugo, additional, and Sozzi, Gabriella, additional

Published
2017
Full Text
View/download PDF

10. P2.01-017 Circulating miRNAs in Lung Cancer Are Associated to Pro-Tumorigenic and Immunosuppressive Microenvironment

Author

Fortunato, Orazio, primary, Borzi, Cristina, additional, Centonze, Giovanni, additional, Milione, Massimo, additional, Conte, Davide, additional, Boeri, Mattia, additional, Verri, Carla, additional, Calzolari, Linda, additional, Andriani, Francesca, additional, Roz, Luca, additional, Huber, Veronica, additional, Cova, Agata, additional, Camisaschi, Chiara, additional, Castelli, Chiara, additional, Rivoltini, Licia, additional, Tripodo, Claudio, additional, Pastorino, Ugo, additional, and Sozzi, Gabriella, additional

Published
2017
Full Text
View/download PDF

12. Therapeutic Use of MicroRNAs in Lung Cancer

Author

Fortunato, Orazio, Boeri, Mattia, Verri, Carla, Moro, Massimo, and Sozzi, Gabriella

Subjects
Article Subject
Abstract

Lung cancer is a leading cause of cancer deaths worldwide. Although the molecular pathways of lung cancer have been partly known, the high mortality rate is not markedly changed. MicroRNAs (miRNAs) are small noncoding RNAs that actively modulate cell physiological processes as apoptosis, cell-cycle control, cell proliferation, DNA repair, and metabolism. Several studies demonstrated that miRNAs are involved in the pathogenesis of lung diseases including lung cancer and they negatively regulate gene and protein expression by acting as oncogenes or tumor suppressors. In this review we summarize the current knowledge on the role of miRNAs and their target genes in lung tumorigenesis and evaluate their potential use as therapeutic agents in lung cancer. In particular, we describe methodological approaches such as inhibition of oncogenic miRNAs or replacement of tumor suppressor miRNAs, both in in vitro and in vivo assays. Furthermore we discuss new strategies to achieve in vivo tissue specific delivery, potential off-target effects, and safety of miRNAs systemic delivery.

Published
2014
Full Text
View/download PDF

16. Abstract 871: Clinical utility of a plasma microRNA biomarker within lung cancer screening

Author

Boeri, Mattia, primary, Verri, Carla, additional, Sozzi, Gabriella, additional, Roz, Luca, additional, Conte, Davide, additional, Suatoni, Paola, additional, Marchiano, Alfonso, additional, Vecchia, Carlo L., additional, Rossi, Marta, additional, Bravi, Francesca, additional, Negri, Eva, additional, Sverzellati, Nicola, additional, and Pastorino, Ugo, additional

Published
2014
Full Text
View/download PDF

17. YAP1acts as oncogenic target of 11q22 amplification in multiple cancer subtypes

Author

Lorenzetto, Erica, primary, Brenca, Monica, additional, Boeri, Mattia, additional, Verri, Carla, additional, Piccinin, Elena, additional, Gasparini, Patrizia, additional, Facchinetti, Federica, additional, Rossi, Sabrina, additional, Salvatore, Giuliana, additional, Massimino, Maura, additional, Sozzi, Gabriella, additional, Maestro, Roberta, additional, and Modena, Piergiorgio, additional

Published
2014
Full Text
View/download PDF

22. YAP1 acts as oncogenic target of 11q22 amplification in multiple cancer subtypes.

Author

Lorenzetto E, Brenca M, Boeri M, Verri C, Piccinin E, Gasparini P, Facchinetti F, Rossi S, Salvatore G, Massimino M, Sozzi G, Maestro R, and Modena P

Subjects
Antineoplastic Agents pharmacology, Apoptosis drug effects, Cell Cycle drug effects, Cell Movement drug effects, Cell Proliferation drug effects, Cell Transformation, Neoplastic genetics, Chemotaxis drug effects, Cisplatin pharmacology, Female, Humans, In Situ Hybridization, Fluorescence, Lung Neoplasms drug therapy, Lung Neoplasms pathology, RNA, Messenger genetics, Real-Time Polymerase Chain Reaction, Reverse Transcriptase Polymerase Chain Reaction, Thyroid Neoplasms drug therapy, Thyroid Neoplasms pathology, Transcription Factors, Tumor Cells, Cultured, Uterine Cervical Neoplasms drug therapy, Uterine Cervical Neoplasms pathology, Wound Healing drug effects, YAP-Signaling Proteins, Adaptor Proteins, Signal Transducing genetics, Cell Transformation, Neoplastic pathology, Chromosomes, Human, Pair 11 genetics, Gene Amplification, Lung Neoplasms genetics, Phosphoproteins genetics, Thyroid Neoplasms genetics, Uterine Cervical Neoplasms genetics
Abstract

The transcriptional coactivator YAP1 is a critical effector of the human Salvador-Warts-Hippo pathway. Literature data report apparently discrepant results on the carcinogenic role of YAP1, which acts either as oncogene or as tumor suppressor in different in vitro and in vivo models. Furthermore, genomic amplification events of 11q22 locus encompassing YAP1 gene have been detected in multiple tumor types but there is limited direct evidence about the oncogenic role of endogenous YAP1 within in the amplicon. We screened a panel of human tumor samples and cancer cell lines and identified that the YAP1 amplification event is actually present in up to 23% of the cases. We exploited EKVX (lung cancer), CaSki (cervical cancer) and RO82 (thyroid cancer) cell lines harboring both genomic YAP1 amplification and YAP1 protein overexpression, in order to study the effects of downregulation of endogenous YAP1 by RNA-interference strategies. Class comparison analysis of gene expression profiling data identified 707 statistically significantly modulated genes (multivariable global test p-value = 0.002) that were functionally annotated for cell proliferation and cellular movement ontologies. Mechanistic studies of the identified perturbed pathways revealed that YAP1 silencing significantly decreased cell proliferation and cell cycle perturbation associated with upregulation of p21 and p27 cell-cycle inhibitors, reduced cell migration (p<0.048) and anchorage-independent growth (p<0.02). In CaSki cell line, YAP1 silencing induced significantly increased sensitivity and cell-death response to cisplatin treatment (p=0.011) as well as reduction of in-vivo tumorigenic potential (p=0.027). Overall, these results establish that YAP1 is a direct oncogenic target of the 11q22 amplicon in previously unreported cancer types and support the relevance of such genetic aberration in carcinogenesis in a fraction of multiple tumor types.

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results